Prometheus Biosciences Inc (RXDX) PT Raised to $117 at Goldman Sachs

December 7, 2022 4:21 PM EST Send to a Friend
Goldman Sachs analyst Chris Shibutani raised the price target on Prometheus Biosciences Inc (NASDAQ: RXDX) to $117.00 (from $60.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login